Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 13 02 2021
accepted: 14 05 2021
entrez: 27 5 2021
pubmed: 28 5 2021
medline: 27 10 2021
Statut: epublish

Résumé

The burden of inflammatory bowel disease (IBD) in Australia is increasing but national data about the current prevalence are limited. We aimed to estimate the prevalence of IBD (including Crohn's disease, ulcerative colitis and unspecified IBD) as well as Crohn's disease and ulcerative colitis separately in a general practice population in Australia. We also assessed risk factors associated with Crohn's disease and ulcerative colitis. We conducted a cross-sectional study using data from MedicineInsight, a national database of general practice electronic health records, from 1 July 2017 to 30 June 2019. The prevalence of IBD was calculated and stratified by sociodemographic characteristics. Logistic regression analysis was conducted to assess risk factors associated with Crohn's disease and ulcerative colitis. The study comprised 2,428,461 regular patients from 481 practices. The estimated crude prevalence of IBD was 653 per 100,000 patients; Crohn's disease was 306 per 100,000 and ulcerative colitis was 334 per 100,000. Males were independently associated with a lower risk of Crohn's disease (OR: 0.86; 95% CI: 0.81, 0.90) but a greater risk of ulcerative colitis (OR: 1.12; 95% CI: 1.06, 1.17) than females. Compared to non-smokers, patients who were current smokers were associated with a greater risk of Crohn's disease (OR: 1.13; 95% CI: 1.04, 1.23) but a lower risk of ulcerative colitis (OR: 0.52; 95% CI: 0.47, 0.57). Other factors positively associated with both Crohn's disease and ulcerative colitis were age (≥ 25 years), non-Indigenous status and socioeconomic advantage. Our findings provide a current estimate of the prevalence of IBD, Crohn's disease and ulcerative colitis in a large national general practice population in Australia and an assessment of the factors associated with Crohn's disease and ulcerative colitis. These data can assist in estimating the health burden and costs, and planning for health services.

Identifiants

pubmed: 34043730
doi: 10.1371/journal.pone.0252458
pii: PONE-D-21-04906
pmc: PMC8158877
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0252458

Déclaration de conflit d'intérêts

I have read the journal’s policy and the authors of this manuscript have the following competing interests: all the authors are employees of NPS MedicineWise, the data custodian of MedicineInsight. NPS MedicineWise receives funding from the Australian Government Department of Health for the MedicineInsight Program.

Références

Nat Methods. 2013 Oct;10(10):921-2
pubmed: 24161969
Lancet. 2007 May 12;369(9573):1627-40
pubmed: 17499605
Ann Hum Genet. 2003 Jan;67(Pt 1):35-41
pubmed: 12556233
Inflamm Bowel Dis. 2006 Oct;12(10):936-43
pubmed: 17012964
J Gastroenterol Hepatol. 2016 Jan;31(1):45-55
pubmed: 25819140
Clin Gastroenterol Hepatol. 2007 Dec;5(12):1424-9
pubmed: 17904915
J Paediatr Child Health. 2014 Apr;50(4):328-9
pubmed: 24698068
J Gastroenterol Hepatol. 2016 Jan;31(1):81-6
pubmed: 26222770
Gut. 2006 Apr;55(4):580
pubmed: 16531539
J Crohns Colitis. 2014 Aug;8(8):717-25
pubmed: 24636140
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30
pubmed: 31648971
Eur J Gastroenterol Hepatol. 2006 Jun;18(6):601-6
pubmed: 16702848
Clin Gastroenterol Hepatol. 2015 Aug;13(8):1453-63.e1
pubmed: 25771246
Int J Epidemiol. 2019 Dec 1;48(6):1741-1741h
pubmed: 31292616
J Gastroenterol. 2010 Jun;45(6):571-83
pubmed: 20213337
BMJ Open. 2020 Jul 19;10(7):e036584
pubmed: 32690524
J Gastroenterol Hepatol. 2010 Feb;25(2):325-33
pubmed: 20074146
Digestion. 2020;101 Suppl 1:98-104
pubmed: 31995797
Intern Med J. 2019 May;49(5):622-630
pubmed: 30230160
Scand J Gastroenterol. 2014 Nov;49(11):1325-35
pubmed: 25259808

Auteurs

Doreen Busingye (D)

Health Intelligence, NPS MedicineWise, Sydney, New South Wales, Australia.

Allan Pollack (A)

Health Intelligence, NPS MedicineWise, Sydney, New South Wales, Australia.

Kendal Chidwick (K)

Health Intelligence, NPS MedicineWise, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH